Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

NCT02388490 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory EBV-and CD30-positive Lymphomas

Interventions

DRUG: brentuximab vedotin

Sponsor

Seoul National University Hospital

Collaborators

[object Object]
[object Object]